Mankind Pharma completed this mega deal for ₹13,768 crores, acquired 100% stake
Drug firm Mankind Pharma has completed a deal to acquire Bharat Serums and Vaccines Ltd (BSV) for Rs 13,768 crore, the company said on Wednesday. According to a PTI report, the company said that this strategic move is a significant leap for the company, establishing it as a market leader in the Indian women’s health and reproductive drug market, and providing access to other high entry barrier products in the critical care segment with an established complex R&D technology platform.
Mankind Pharma’s position will be strengthened
According to the news, BSV has developed recombinant and niche biological products in-house, demonstrating its strong R&D capabilities and boasts a strong branded product portfolio in women’s health, fertility, critical care and immunoglobulins. Rajiv Juneja, Vice Chairman and Managing Director, Mankind Pharma, said that today, we warmly welcome more than 2,500 members of BSV to the Mankind family, adding a new chapter to our exciting journey and setting the stage for accelerated growth.
Wide access to complex treatments will be ensured
BSV MD and CEO Sanjeev Navangul said that becoming a part of the Mankind Pharma family makes BSV bigger, stronger and better. Now together we will be able to ensure wide access to our exclusive and indigenously developed complex treatments to millions of patients in India and around the world. Together we will open up new possibilities, explore opportunities and maximize potential that will help achieve our priorities and business goals. In July this year, MannKind had announced that it would acquire 100 percent stake in BSV.
